Free Trial

OnKure Therapeutics Q4 2022 Earnings Report

OnKure Therapeutics logo
$8.61 -0.12 (-1.37%)
(As of 12/18/2024 05:44 PM ET)

OnKure Therapeutics EPS Results

Actual EPS
-$5.60
Consensus EPS
-$6.20
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

OnKure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OnKure Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

OnKure Therapeutics Earnings Headlines

Oppenheimer Remains a Buy on OnKure Therapeutics (OKUR)
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
OnKure Therapeutics Advances Cancer Drug Trials
See More OnKure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email.

About OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.

View OnKure Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings